The North America RNA Analysis Market is expected to witness market growth of 15.1% CAGR during the forecast period (2022-2028).
A cell's identity is determined by the transcription of a subset of its genes into complementary RNA molecules, which also controls the biological processes taking place inside the cell. These are crucial for deciphering the functional components of the genome and comprehending development and illness. The transcriptome is extremely complicated and contains several coding and non-coding RNA species. Historically, according to the fundamental tenet of molecular biology, RNA molecules were considered to be merely an intermediary between genes and proteins.
Because they used the genetic code to encode proteins, messenger RNA molecules were the most widely investigated RNA species. There is a wide variety of noncoding RNA molecules that are functional in addition to protein-coding mRNA. Most ncRNAs were previously thought to perform fundamental cellular tasks, such as those carried out by ribosomal and transfer RNAs in mRNA translation, small nuclear RNAs in splicing, and small nucleolar RNAs that modify rRNAs.
Currently, healthcare providers are seeking ways to streamline their processes, especially concerning planning and invoicing for virtual treatment. As the use, transmission, and availability of digital health information increases, providers are required to implement stronger and more sophisticated cybersecurity measures and encryption to protect patient privacy. A significant market may exist for platforms that connect to Prescribe IT, Canada's national e-prescription system. The prevalence of chronic diseases and the aging of the population are increasing demand in the Canadian healthcare sector.
The US market dominated the North America RNA Analysis Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $8,226.8 million by 2028. The Canada market is poised to grow at a CAGR of 17.7% during (2022 - 2028). Additionally, The Mexico market is expected to witness a CAGR of 16.7% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Reagents, Instruments and Services. Based on Technology, the market is segmented into Real Time-PCR (qPCR) Technology, Sequencing Technology, Microarray Technology and Others. Based on End-use, the market is segmented into Government Institutes & Academic Centers, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies and Contract Research Organizations (CROs). Based on Application, the market is segmented into Infectious Diseases & Pathogenesis, Epigenetics, RNA Structure & Molecular Dynamics, Development & Delivery of RNA Therapeutics, Construction of RNA Expression Atlas, Alternative RNA Splicing and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Eurofins Scientific Group, Merck Group, and Promega Corporation.
A cell's identity is determined by the transcription of a subset of its genes into complementary RNA molecules, which also controls the biological processes taking place inside the cell. These are crucial for deciphering the functional components of the genome and comprehending development and illness. The transcriptome is extremely complicated and contains several coding and non-coding RNA species. Historically, according to the fundamental tenet of molecular biology, RNA molecules were considered to be merely an intermediary between genes and proteins.
Because they used the genetic code to encode proteins, messenger RNA molecules were the most widely investigated RNA species. There is a wide variety of noncoding RNA molecules that are functional in addition to protein-coding mRNA. Most ncRNAs were previously thought to perform fundamental cellular tasks, such as those carried out by ribosomal and transfer RNAs in mRNA translation, small nuclear RNAs in splicing, and small nucleolar RNAs that modify rRNAs.
Currently, healthcare providers are seeking ways to streamline their processes, especially concerning planning and invoicing for virtual treatment. As the use, transmission, and availability of digital health information increases, providers are required to implement stronger and more sophisticated cybersecurity measures and encryption to protect patient privacy. A significant market may exist for platforms that connect to Prescribe IT, Canada's national e-prescription system. The prevalence of chronic diseases and the aging of the population are increasing demand in the Canadian healthcare sector.
The US market dominated the North America RNA Analysis Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $8,226.8 million by 2028. The Canada market is poised to grow at a CAGR of 17.7% during (2022 - 2028). Additionally, The Mexico market is expected to witness a CAGR of 16.7% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Reagents, Instruments and Services. Based on Technology, the market is segmented into Real Time-PCR (qPCR) Technology, Sequencing Technology, Microarray Technology and Others. Based on End-use, the market is segmented into Government Institutes & Academic Centers, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies and Contract Research Organizations (CROs). Based on Application, the market is segmented into Infectious Diseases & Pathogenesis, Epigenetics, RNA Structure & Molecular Dynamics, Development & Delivery of RNA Therapeutics, Construction of RNA Expression Atlas, Alternative RNA Splicing and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Eurofins Scientific Group, Merck Group, and Promega Corporation.
Scope of the Study
Market Segments Covered in the Report:
By Product- Kits & Reagents
- Instruments
- Services
- Real Time-PCR (qPCR) Technology
- Sequencing Technology
- Microarray Technology
- Others
- Government Institutes & Academic Centers
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Infectious Diseases & Pathogenesis
- Epigenetics
- RNA Structure & Molecular Dynamics
- Development & Delivery of RNA Therapeutics
- Construction of RNA Expression Atlas
- Alternative RNA Splicing
- Others
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Qiagen N.V.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Eurofins Scientific Group
- Merck Group
- Promega Corporation
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. North America RNA Analysis Market by Product
Chapter 5. North America RNA Analysis Market by Technology
Chapter 6. North America RNA Analysis Market by End-use
Chapter 7. North America RNA Analysis Market by Application
Chapter 8. North America RNA Analysis Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Qiagen N.V.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Eurofins Scientific Group
- Merck Group
- Promega Corporation
Methodology
LOADING...
